Loading…
Alvotech is projected to rise to $3.38 by 2027, a +3% move from its current price of $3.28. ALVO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $3.18 | $3.28 | $3.39 | +0.01% |
| Jul 14 | $3.13 | $3.28 | $3.43 | +0.01% |
| Jul 15 | $3.10 | $3.28 | $3.47 | +0.02% |
| Jul 16 | $3.07 | $3.28 | $3.50 | +0.03% |
| Jul 17 | $3.05 | $3.28 | $3.53 | +0.04% |
| Jul 18 | $3.03 | $3.28 | $3.55 | +0.04% |
| Jul 19 | $3.01 | $3.28 | $3.58 | +0.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.01 | $3.28 | $3.58 | +0.05% |
| Week 2 | $2.91 | $3.28 | $3.71 | +0.10% |
| Week 3 | $2.83 | $3.29 | $3.81 | +0.15% |
| Week 4 | $2.77 | $3.29 | $3.90 | +0.20% |
| Week 5 | $2.71 | $3.29 | $3.99 | +0.26% |
| Week 6 | $2.67 | $3.29 | $4.06 | +0.31% |
| Week 7 | $2.62 | $3.29 | $4.13 | +0.36% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.
In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
ALVO is a healthcare stock with a current price of $3.48, a market cap of $1.18B, and a rank of 2433. The near-term price path is framed by a mixed setup in the forecast, with 2026 showing an average of $3.48 and later years projecting higher values, including 2030 at an average of $3.69, 2040 at $6.38, and 2050 at $13.77. These figures imply meaningful long-run upside despite a modest near-term tone.
The stock operates in the healthcare sector and carries a near-term technical backdrop that investors may weigh against the long-run projections.
A major floor 30.9% below — a decisive break under it would weaken the trend.
The nearest floor, 8.5% below — buyers have tended to step in here.
The nearest ceiling, 29.3% above — a clean break opens room to run.
A major ceiling 44.7% above — clearing it would confirm fresh momentum.
Key ALVO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ALVO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.39 | Sell | $3.39 | Sell |
| MA 10 | $3.52 | Sell | $3.49 | Sell |
| MA 20 | $3.70 | Sell | $3.58 | Sell |
| MA 50 | $3.56 | Sell | $3.63 | Sell |
| MA 100 | $3.63 | Sell | $3.92 | Sell |
| MA 200 | $4.84 | Sell | $4.95 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.71 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -133.46 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | -11.35 | Sell |
| Bollinger %B (20,2) | 0.11 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.03 | Sell |
| Awesome (5,34) | -0.25 | Sell |
| Ultimate (7,14,28) | 20.93 | Buy |
| Momentum (10) | -0.20 | Sell |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 3.29 | Sell |
| ADX (14) | 12.21 | Neutral |
| ATR (14) | 0.11 | Info |
The 30-day technical picture is Bearish, with RSI14 at 40. This suggests softer near-term momentum despite the stock trading near key levels. The chart shows the SMA50 at $3.56 and the SMA200 at $5.07, indicating the shorter-term moving average sits just below the longer-term gauge.
Support is identified at $3.00, while resistance stands at $4.24. The 30-day range spans from $2.68 to $4.52, outlining a broad trading corridor over the period.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.00 | $3.28 | $4.51 | 0% | Neutral | |
| $2.65 | $3.38 | $4.61 | +3% | Neutral | |
| $2.65 | $3.50 | $4.98 | +7% | Neutral | |
| $2.45 | $3.33 | $4.89 | +2% | Neutral | |
| $2.60 | $3.63 | $5.48 | +11% | Neutral | |
| $3.25 | $4.64 | $7.18 | +42% | Bullish | |
| $3.14 | $4.59 | $7.26 | +40% | Bullish | |
| $3.22 | $4.80 | $7.74 | +46% | Bullish | |
| $3.36 | $5.09 | $8.36 | +55% | Bullish | |
| $2.96 | $4.57 | $7.64 | +39% | Bullish | |
| $3.94 | $6.64 | $11.88 | +102% | Bullish | |
| $7.07 | $13.82 | $27.37 | +321% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.00 | $3.28 | $4.00 | +0.00% |
| August 2026 | $2.78 | $3.30 | $4.04 | +0.75% |
| September 2026 | $2.76 | $3.30 | $4.09 | -0.08% |
| October 2026 | $2.88 | $3.47 | $4.35 | +5.13% |
| November 2026 | $2.95 | $3.58 | $4.52 | +3.08% |
| December 2026 | $2.90 | $3.54 | $4.51 | -1.19% |
Click any year to see its month-by-month ALVO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Alvotech's 2026 outlook centres on $3.28, within a $3.00 to $4.51 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, ALVO could reach as high as $4.61, with a base case around $3.38 and support toward $2.65 — roughly +3% from $3.28. Price action looks broadly range-bound.
Expect ALVO to range from $2.65 to $4.98 through 2028. The $3.50 average target implies a +7% move from current prices. That is up +4% on the projected 2027 average. A consolidation phase looks the most probable path here.
The ALVO price prediction for 2029 points to an average of $3.33 (low $2.45, high $4.89) — a potential gain of +2% on today's $3.28. Price action looks broadly range-bound.
In 2030, ALVO is projected to trade between $2.60 and $5.48, averaging $3.63 — a potential gain of +11% from today's $3.28. That is up +9% on the projected 2029 average. A consolidation phase looks the most probable path here.
Alvotech's 2031 outlook centres on $4.64, within a $3.25 to $7.18 range. That is up +28% on the projected 2030 average. That marks a +42% change versus current levels. Momentum favours further upside here.
By 2032, ALVO could reach as high as $7.26, with a base case around $4.59 and support toward $3.14 — roughly +40% from $3.28. Buyers look set to stay in control over this stretch.
Expect ALVO to range from $3.22 to $7.74 through 2033. The $4.80 average target implies a +46% move from current prices. That is up +5% on the projected 2032 average. Momentum favours further upside here.
The ALVO price prediction for 2034 points to an average of $5.09 (low $3.36, high $8.36) — a potential gain of +55% on today's $3.28. Buyers look set to stay in control over this stretch.
In 2035, ALVO is projected to trade between $2.96 and $7.64, averaging $4.57 — a potential gain of +39% from today's $3.28. That is -10% versus the projected 2034 average. Momentum favours further upside here.
Alvotech's 2040 outlook centres on $6.64, within a $3.94 to $11.88 range. That is up +45% on the projected 2035 average. That marks a +102% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, ALVO could reach as high as $27.37, with a base case around $13.82 and support toward $7.07 — roughly +321% from $3.28. Momentum favours further upside here.
Investing $1,000 in ALVO today (≈ 304.878049 ALVO) could be worth
$4,214.68
+$3,214.68 (+321%) by 2050 · US Dollar
Based on the average projected ALVO price of $13.82 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ALVOwould be worth at today's price.
$1,000 invested in ALVO on Jul 10, 2025 (≈ 114.547543 ALVO) would be worth
$375.72
-$624.28 (-62.4%) today · 0.38× · US Dollar
Based on a ALVO entry price of $8.73 vs. today's $3.28.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.61 | $908.59 | -9.1% |
| 1 month ago | $4.14 | $792.27 | -20.8% |
| 3 months ago | $3.62 | $906.08 | -9.4% |
| 6 months ago | $4.93 | $665.31 | -33.5% |
| 1 year ago | $8.73 | $375.72 | -62.4% |
| All time (4.1y) ago | $11.19 | $293.12 | -70.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ALVO forecast.
Our base-case forecast reaches $6.60 around 2040.
Implied market cap at $6.60: $2.23B
The multi-year forecast moves from neutral to bullish across the horizon. The 2026–2029 window is labeled Neutral, with 2026–2029 averages around the mid-single digits and modest max/min ranges. The 2030 forecast shows an average of $3.69 with a 6% ROI, signaling a potential step-up in pricing resilience.
By 2031–2035 the outlook turns bullish, with yearly averages rising toward $4.69–$5.08 and ROIs in the mid-to-high teens to low 40s, reflecting stronger upside momentum.
Tap a question to reveal the answer.
2030: avg $3.69, min $2.52, max $5.86, ROI 6%, sentiment NEUTRAL.
The forecast shows Neutral sentiment in 2026–2029, turning Bullish from 2031 onward, with notable upside in later years (2031 avg $4.69, ROI 34.7%; 2032 avg $4.65, ROI 33.6%; 2033 avg $4.95, ROI 42.3%; 2034 avg $5.08, ROI 46%). These are estimates, not guarantees.
Yes, the max values in the forecast exceed $5 in several years: 2030 max $5.86, 2031 max $7.66, 2032 max $7.79, 2033 max $8.49, 2034 max $8.89, 2040 max $12.30, and 2050 max $29.74.
2026: min $3.00, avg $3.48, max $4.94, ROI 0%, sentiment NEUTRAL.
Annualized volatility is 80%.
Alvotech Community Discussion
0Share your Alvotech price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.